BioSpace News Archive

CAGE Bio Inc. and TAGCyx Biotechnologies Inc. announce the execution of a license agreement for development of TAGX-0003 for the targeted treatment of alopecia areata and vitiligo by dermatological application.

Valent BioSciences LLC, the global biorational products leader in agriculture, public health, and forestry, has announced the promotion of Salman Mir to Executive Vice President and Chief Operating Officer.

Celularity Inc., a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, announced that it entered into a Pre-Paid Advance Agreement with YA II PN, LTD, an affiliate of Yorkville Advisors Global, LP.

On September 13-14, 2022 the National Drowning Prevention Alliance (NDPA.org) hosted the industry’s first research summit solely dedicated to water safety and drowning prevention for children and adolescents - a critical issue and the single leading cause of death among children ages 1-4 years old.

NewHaptics, an innovative tactile display technology company, announced it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH).

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), today announced that its chief executive officer, Nima Farzan, will participate in the Piper Sandler Heartland Summit as part of the panel “Healthcare Politics: FDA Proposals from Optimus, to ORBIS to RTOR and CONFIRM – How Might These Proposals Impact Oncology Drug Development and Implications?” on Thursday, September 22, 2022 at 11:30 a.m. C.T.

Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people living with sickle cell disease (SCD) will use Folia’s innovative technology platform to track their individual changes in symptoms and treatment use.

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2022.

Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.